Mallory Danielson
Psychiatric/Mental Health · Murray, UTNPI 1104224815
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 29.0% of the total. Reporting peaked in 2023 at $893 and has fallen 97.8% since, to $19 in 2025. Among psychiatric/mental health clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$951
- Johnson & Johnson$435
- Supernus Pharmaceuticals, Inc.$312
- Teva Pharmaceuticals USA, Inc.$238
- Neurocrine Biosciences, Inc.$201
- Alkermes, Inc.$154
- plus $993 from 12 others
What the payments were for
- Food & beverage$3,284100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $951 |
| Johnson & Johnson | 18 | $435 |
| Supernus Pharmaceuticals, Inc. | 5 | $312 |
| Teva Pharmaceuticals USA, Inc. | 15 | $238 |
| Neurocrine Biosciences, Inc. | 8 | $201 |
| Alkermes, Inc. | 9 | $154 |
| Otsuka America Pharmaceutical, Inc. | 8 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $136 |
| Lundbeck LLC | 6 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $105 |
| Idorsia Pharmaceuticals US Inc | 6 | $104 |
| Sunovion Pharmaceuticals Inc. | 6 | $101 |
| Axsome Therapeutics, Inc. | 4 | $65 |
| Bausch Health US, LLC | 4 | $64 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Indivior Inc. | 3 | $58 |
| Alfasigma USA, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,284 in reported general payments places this provider in the 90th percentile of 393 psychiatric/mental health providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 13 | $239 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Murray
- Karen RischMurray$5K
- Lindsey GavinMurray$4K
- Maurice FiedelMurray$3K
- Taylor SublettMurray$3K
- Virginia FischerMurray$3K
- Bret HafenLayton$381K
- Alberto SouzaSaint George$114K
- Anthony BrowningOrem$32K
- Debra HainRiverton$29K
- Kristin BarberSalt Lake City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.